We are very pleased to welcome David to the Company and are fortunate to have him lead the charge on the Ultroid® Care Centers, while also focusing on enhancing our companies' marketing efforts to drive awareness. Mr. Vautrin has had an impactful, highly successful career as an entrepreneur and executive with both private organizations and multi-billion dollar enterprises
St. Petersburg, FL (PRWEB) September 15, 2008
Vascular Technologies Inc. announces today that David Vautrin, former Senior Vice President of Cott Corporation, is appointed as Chief Executive Officer of the Ultroid Care Centers and Chief Marketing Officer of Ultroid Technologies and Vascular Technologies effective immediately.
Prior to joining Vascular Technologies, Inc. and Ultroid Technologies, Inc., Mr. Vautrin was the Senior Vice President for Cott Corporation (COT), SVP for Indulgent Foods and General Manager for H.P. Hood. Additionally, he owned and operated two successful businesses which he developed and sold.
"We are very pleased to welcome David to the Company and are fortunate to have him lead the charge on the Ultroid® Care Centers, while also focusing on enhancing our companies' marketing efforts to drive awareness. Mr. Vautrin has had an impactful, highly successful career as an entrepreneur and executive with both private organizations and multi-billion dollar enterprises," Brent Willis, CEO.
"Ultroid® Care Centers, a subsidiary of Vascular Technologies Inc., are streamline medical wellness centers designed to offer relief to the near 45 million patients suffering from Rectal Varicosities (RV), hemorrhoids, and other varicose vein disorders. RV affects nearly 75% of the people on the planet over age 45 and Ultroid is the only painless and effective treatment of this debilitating disease. The Physician run care centers will more rapidly expand the Ultroid-Solution™ and compliment the forward thinking medical partners joining and already part of the Ultroid® network.
The Ultroid® Care Clinics offer additional accessibility for treatment at a cost that can be often as little as a co-pay, given the procedure's attractive reimbursements from Medicare, most leading insurance providers and Worker's Compensation. "The ultimate objective is Patient wellness and eliminating the 3rd fastest growing disease worldwide. This purpose is what excites me the most" said Vautrin.
"David's strategic business planning and general management expertise will accelerate the Ultroid® Care Center business while his "Best in Class" marketing and brand building will connect the Ultroid® Brand with our Medical Partners." commented Michael Cao, Chairman of the Board of Directors. "The Board is confident that David's leadership and experience will significant accelerate Ultroid's distribution expansion."
Vascular Technologies, Inc. is the owner of the Ultroid® medical device that has shown over 90% effectiveness in the treatment of hemorrhoids. Unlike current surgical treatments, the Ultroid-Solution™ is a painless outpatient procedure with immediate recovery, and has potential applications for the treatment of other varicose and spider veins.
"I am extremely excited to join Vascular Technologies and the Ultroid® Team. The Ultroid Solution™ is a genuine breakthrough for the treatment of this pervasive global issue. Ultroid® is the most advanced standard of care in Hemorrhoid treatment. This is a global condition that is non-discriminatory, non-gender specific and frankly affects an extremely wide consumer base especially athletes, anyone under strain (child-bearing women, vehicle operators, pilots) and more than 75% of the world's population aged over 50. Research indicates that it is not "if", but "when" a patient needs a solution to RV, and early treatment precludes more advanced stages of RV. Broad-scale brand awareness building and a new no-cost entry program for our medical partners will be critical components of my strategy to bring patients, the medical community and the Ultroid-Solution™ together."
About Vascular Technologies and Ultroid Technologies
Vascular Technologies, Inc. is one of the fastest growing medical device companies in the United States. Its principal product is the breakthrough Ultroid® Medical System, a less expensive and more effective treatment than current procedures for hemorrhoids with new applications for other varicose and spider veins. Ultroid® is a painless, non-invasive outpatient treatment with an over 90% effective rate that replaces ineffective over-the-counter creams and painful surgeries that are often accompanied by infection and prolonged recovery. The Ultroid® procedure can be performed by any physician, regardless of specialty, in their office, in approximately 10-15 minutes. Patients are able to resume their normal daily activities immediately, versus the several month recovery often associated with current laser and other surgical treatments. Ultroid® is FDA-cleared and accepted by most insurers and Medicare.
The Company's website is http://www.Ultroid.com. The brand names referenced in this press release are trademarks of Vascular Technologies, Inc. and Ultroid® Technologies, Inc. its affiliated companies, customers, or other third parties. The Company manages web video-enabled training clinics, Ultroid Care wholly-owned and franchised treatment clinics, and markets and manufactures the Ultroid® Medical Devices.
Safe Harbor Statements
This press release may contain forward-looking statements reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
VASCULAR TECHNOLOGIES, INC. AND ULTROID TECHONOLIES, INC. CONTACTS:
Media and Investor Relations
Tel: (877) 858-0555